Summary

Revenue : 000,000 M USD
Finance : 000,000 M USD
Earning Cap : 000,000 M USD
Invest : 000,000 M USD
R & D : 0000 People
Growth : 00% AGR

DIGDAL CAP

Overview

General Introduction Nanhua Biopharmaceutical Co., Ltd. is a high-tech biopharmaceutical technology company based on stem cell and regenerative medicine, driven by clinical cell transformation research and application, with a focus on cell storage, health management, beauty and anti-aging fields. Through the layout and efforts in the entire health industry chain, we aim to create a world-class biotechnology company. Nanhua Biology has formed a top scientist matrix with the Nobel Prize winner and Academician of the American Academy of Sciences Samenza as the strategic guidance, CAE Member Zhou Honghao as the chairman of the expert committee, CAS Member as the consultant, postdoctoral fellows of Harvard University as the backbone, and national 973/863 subject experts as the professional combination. The company has advanced cytology technology, built a world-class cell laminar flow culture room, created a scientific and efficient cell clinical application research system, and has rich experience in cell clinical research. As a state-owned listed company with the Hunan Provincial Government as the actual controller and Hunan Caixin Financial Holding Group as the largest shareholder, Nanhua Biotech takes "caring for the health of the people and benefiting the public" as its own responsibility, focusing on the biotechnology industry and promoting a new leap in human health.
Headquarter Changsha
Establish Date 10/18/1991
Listed Code 000504.SZ
Listed Date 12/8/1992
Chairman Yang Yun.
CEO You Changqiao.
Website www.landfar.cn

Buy Premium Now

$15/month billed now

View the full stack of insights immediately

Or 7 Days Free Charge for Trial

See feature available in the Trial and Premium

See our Solution and Servicetrial.solutionservice.trial

See our Uniquness and Value deliveringtrial.solutionservice.trial